Gain-of-function mutations in the phosphatidylserine synthase 1 (PTDSS1) gene cause Lenz-Majewski syndrome
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu časopisecké články, Research Support, N.I.H., Extramural, práce podpořená grantem
Grantová podpora
G1001689
Medical Research Council - United Kingdom
Wellcome Trust - United Kingdom
G0802462
Medical Research Council - United Kingdom
HL-102926
NHLBI NIH HHS - United States
HL-102925
NHLBI NIH HHS - United States
HL-102923
NHLBI NIH HHS - United States
MR/K01417X/1
Medical Research Council - United Kingdom
HL-103010
NHLBI NIH HHS - United States
MR/L009978/1
Medical Research Council - United Kingdom
HL-102924
NHLBI NIH HHS - United States
PubMed
24241535
DOI
10.1038/ng.2829
PII: ng.2829
Knihovny.cz E-zdroje
- MeSH
- dánio pruhované embryologie genetika MeSH
- dítě MeSH
- embryo nesavčí MeSH
- fibroblasty metabolismus MeSH
- fosfatidylseriny biosyntéza genetika MeSH
- hyperostóza MeSH
- kultivované buňky MeSH
- lidé MeSH
- mladiství MeSH
- mnohočetné abnormality genetika MeSH
- molekulární sekvence - údaje MeSH
- mutace * MeSH
- nanismus MeSH
- syndrom MeSH
- transferasy dusíkatých skupin genetika metabolismus MeSH
- zvířata MeSH
- Check Tag
- dítě MeSH
- lidé MeSH
- mladiství MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Research Support, N.I.H., Extramural MeSH
- Názvy látek
- fosfatidylseriny MeSH
- phospholipid serine base exchange enzyme MeSH Prohlížeč
- transferasy dusíkatých skupin MeSH
Lenz-Majewski syndrome (LMS) is a syndrome of intellectual disability and multiple congenital anomalies that features generalized craniotubular hyperostosis. By using whole-exome sequencing and selecting variants consistent with the predicted dominant de novo etiology of LMS, we identified causative heterozygous missense mutations in PTDSS1, which encodes phosphatidylserine synthase 1 (PSS1). PSS1 is one of two enzymes involved in the production of phosphatidylserine. Phosphatidylserine synthesis was increased in intact fibroblasts from affected individuals, and end-product inhibition of PSS1 by phosphatidylserine was markedly reduced. Therefore, these mutations cause a gain-of-function effect associated with regulatory dysfunction of PSS1. We have identified LMS as the first human disease, to our knowledge, caused by disrupted phosphatidylserine metabolism. Our results point to an unexplored link between phosphatidylserine synthesis and bone metabolism.
] Centre for Translational Genomics GOSgene UCL Institute of Child Health London UK [2]
] Molecular Medicine Unit UCL Institute of Child Health London UK [2]
Clinical and Molecular Genetics Unit University College London Institute of Child Health London UK
Clinical Genetics Department Great Ormond Street Hospital London UK
Department of Medical Genetics Children's Memorial Health Institute Warsaw Poland
Histopathology Department Great Ormond Street Hospital for Children London UK
Neural Development Unit UCL Institute of Child Health London UK
Zobrazit více v PubMed
J Biol Chem. 1986 May 5;261(13):5784-9 PubMed
J Biol Chem. 1998 Mar 27;273(13):7293-302 PubMed
Am J Med Genet. 2000 Mar 20;91(3):198-200 PubMed
Birth Defects Orig Artic Ser. 1974;10(12):133-6 PubMed
J Biol Chem. 1998 Jul 3;273(27):17199-205 PubMed
Am J Med Genet A. 2012 Sep;158A(9):2091-9 PubMed
Clin Dysmorphol. 2004 Jul;13(3):137-142 PubMed
J Inherit Metab Dis. 2011 Aug;34(4):907-16 PubMed
J Biol Chem. 2011 Jan 14;286(2):1061-73 PubMed
Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4199-203 PubMed
Biochim Biophys Acta. 2013 Mar;1831(3):543-54 PubMed
Development. 2006 Dec;133(23):4619-30 PubMed
Trends Genet. 2005 Nov;21(11):586-90 PubMed
J Cell Biochem. 2009 Jan 1;106(1):127-38 PubMed
J Biol Chem. 2008 Feb 15;283(7):3827-38 PubMed
J Immunol. 2010 Mar 15;184(6):3191-201 PubMed
Can J Biochem Physiol. 1959 Aug;37(8):911-7 PubMed
J Pediatr. 1977 Sep;91(3):417-21 PubMed
Nat Genet. 2009 Sep;41(9):1016-21 PubMed
Nature. 2010 Oct 28;467(7319):1061-73 PubMed
Am J Med Genet. 2000 Aug 14;93(4):335-8 PubMed
Am J Med Genet. 1989 Apr;32(4):470-4 PubMed
Radiology. 1983 Oct;149(1):129-31 PubMed
Nucleic Acids Res. 2001 Jan 1;29(1):308-11 PubMed
Lipids. 1966 Jan;1(1):85-6 PubMed
J Biol Chem. 2002 Dec 6;277(49):47701-8 PubMed
Am J Med Genet A. 2011 May;155A(5):943-68 PubMed
J Lipid Res. 2012 Feb;53(2):325-30 PubMed
J Biol Chem. 2001 Mar 16;276(11):8205-12 PubMed
J Clin Invest. 1976 May;57(5):1221-6 PubMed
Curr Treat Options Neurol. 2011 Oct;13(5):520-8 PubMed
J Can Assoc Radiol. 1974 Mar;25(1):22-33 PubMed
Sports Med. 2006;36(8):657-69 PubMed
Nat Genet. 2008 Mar;40(3):284-6 PubMed
Biochem J. 2009 Mar 1;418(2):421-9 PubMed
Molecules. 2009 Dec 22;14(12):5367-81 PubMed
Annu Rev Biophys. 2010;39:407-27 PubMed
Am J Dis Child. 1974 Jan;127(1):115-7 PubMed
Neurochem Res. 2003 Feb;28(2):195-214 PubMed
Biochem J. 1999 Aug 15;342 ( Pt 1):57-64 PubMed
Dev Biol. 2011 Feb 15;350(2):279-89 PubMed
J Biol Chem. 2008 May 9;283(19):12888-97 PubMed
Hum Genet. 2012 Nov;131(11):1761-73 PubMed
Biochem J. 2004 Aug 1;381(Pt 3):853-9 PubMed
J Biol Chem. 1999 Aug 20;274(34):23844-9 PubMed
Hum Mol Genet. 2009 Jun 15;18(12):2149-65 PubMed
J Biol Chem. 2000 Nov 3;275(44):34534-40 PubMed
Hum Mol Genet. 2011 Mar 1;20(5):948-61 PubMed
Oral Surg Oral Med Oral Pathol. 1969 Jan;27(1):20-6 PubMed
Cutis laxa and excessive bone growth due to de novo mutations in PTDSS1